


Growing number of biologic therapies offers **future opportunities** for biosimilar development



Over the next 15 years, more than 100 biologic medicines (mainly monoclonal antibodies) will lose market protection and open to biosimilar competition in existing and new therapy areas, incl. for orphan indications (20%)
Source IQVIA Spotlight on Biosimilars and IQVIA (2021) The Prospect of Biosimilars of orphan drugs in Europe. (2020)